Antidepressant discontinuation syndrome

Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

Retrieved on: 
Thursday, September 21, 2023
CAH, Neurocrine Biosciences, ESPE, Antidepressant discontinuation syndrome, Adrenocorticotropic hormone, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency, Vital signs, Patient, SAN, Adolescence, Androstenedione, European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria, ACTH, GC, Safety, Pharmaceutical industry, Birth control, The Hague, A4

SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug crinecerfont in adolescent patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).

Key Points: 
  • SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug crinecerfont in adolescent patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).
  • These new data will be presented at the 61st Annual European Society for Pediatric Endocrinology ( ESPE ) Meeting in The Hague, Netherlands from Sept. 21–23, 2023.
  • Post hoc analysis of these data released today assessed whether baseline hormone concentration and glucocorticoid (GC) doses correlated with response to treatment.
  • We plan to announce top-line data from our Phase 3 CAHtalyst™ Pediatric Study in early Q4 2023."

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

Retrieved on: 
Monday, January 9, 2023
World Health Organization, Neuropsychiatric Disease and Treatment, Therapy, Quantitative electroencephalography, Lorazepam, GABA, Antidepressant discontinuation syndrome, Social anxiety disorder, Panic disorder, Mental health, Safety, SAD, MD, GAD, Central nervous system, Alprazolam, Anxiety, MAD, CMO, Doctor of Philosophy, Benzodiazepine, Hypoventilation, Vaccine, Medical imaging, Pharmaceutical industry

GRX-917 was well tolerated with sedation comparable to placebo noted over the entirety of the dose range explored.

Key Points: 
  • GRX-917 was well tolerated with sedation comparable to placebo noted over the entirety of the dose range explored.
  • Initiation of a GRX-917 efficacy study is anticipated in H1 2023 with results expected in 2024.
  • NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day.
  • The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety, tolerability, and pharmacokinetic profile of single and multiple ascending doses of orally administered GRX-917.

Vasculitis Pipeline Insights Report 2022: Comprehensive Insights about 40+ Companies and 40+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 21, 2022
Health, Pharmaceutical, Giant, Amputation, NDA, GCA, News, C5a, Giant cell arteritis, Clinical trial, Axial spondyloarthritis, Antidepressant discontinuation syndrome, ANCA, B-cell activating factor, Research, Psoriasis, Giant cell, Novartis, Route of administration, E-selectin, Route, Inflammation, Time-invariant system, III, Psoriatic arthritis, Inactive, AAV, Technology, Discovery, Secukinumab, Blood, ROA, Belimumab, Administration, Acquisition, Vascular disease, Regeneration, Survival, Medical device, Pharmaceutical industry, Vaccine, Vasculitis

The "Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vasculitis pipeline landscape.

Key Points: 
  • The "Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vasculitis pipeline landscape.
  • The assessment part of the report embraces, in depth Vasculitis commercial assessment and clinical assessment of the pipeline products under development.
  • Companies and academics are working to assess challenges and seek opportunities that could influence Vasculitis R&D.
  • Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Palmar Hyperhidrosis Pipeline Market Insights Report 2022 Featuring Key Players - Atacama Therapeutics, GlaxoSmithKline, Brickell Biotech, & Candesant Biomedical - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 21, 2022
Health, Pharmaceutical, NDA, News, Hyperhidrosis, Clinical trial, Antidepressant discontinuation syndrome, Umeclidinium bromide, Route of administration, Therapy, Route, II, GlaxoSmithKline, Inactive, Technology, Discovery, ROA, Administration, Acquisition, Mecamylamine, Muscarinic acetylcholine receptor, Pharmaceutical industry

The "Palmar Hyperhidrosis - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Palmar Hyperhidrosis pipeline landscape.

Key Points: 
  • The "Palmar Hyperhidrosis - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Palmar Hyperhidrosis pipeline landscape.
  • A detailed picture of the Palmar Hyperhidrosis pipeline landscape is provided which includes the disease overview and Palmar Hyperhidrosis treatment guidelines.
  • The assessment part of the report embraces in depth Palmar Hyperhidrosis commercial assessment and clinical assessment of the pipeline products under development.
  • Palmar Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.